Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic modified 16-amino acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH residues 177-191), with a single Tyrosine added at the N-terminus for stability. The compound was developed in the late 1990s by Professor Frank Ng's group at Monash University in Melbourne, Australia, and commercialized by Metabolic Pharmaceuticals Limited (now defunct) with the goal of creating a fat-loss drug that retained growth hormone's lipolytic effects without the unwanted growth-promoting, IGF-1-stimulating, and insulin-disrupting effects of full-length hGH.
AOD-9604 represents one of the more revealing examples of pharmaceutical drug development failure followed by strategic pivot. The trajectory:
- Original goal: FDA approval as obesity treatment
- Phase 1/2 trials (6 trials, ~900 participants): demonstrated excellent safety; some weight loss signals
- Phase 3 / 12-week trial (2007): modest weight loss (2.6 kg AOD-9604 vs 0.8 kg placebo; statistically significant but clinically modest)
- Critical follow-up: when intensive diet+exercise was incorporated, the weight loss signal disappeared. AOD-9604 effects may not add to lifestyle intervention
- FAILED regulatory submission: insufficient efficacy magnitude for FDA obesity approval
- Strategic pivot: repositioned as cosmetic ingredient
- Australian TGA approval as cosmetic/nutraceutical ingredient, NOT pharmaceutical approval anywhere
- Metabolic Pharmaceuticals dissolution: original developer now defunct
- Modern use: research chemical for fat loss applications; widely sold despite Phase 3 failure
AOD-9604 is essentially an obsolete-class drug relative to modern obesity treatments. The efficacy comparison is stark:
| Drug | Weight loss (1 year) |
|---|---|
| AOD-9604 | 2-3 kg (3-4%) |
| Phentermine/topiramate | ~10% |
| Liraglutide | ~5-8% |
| Semaglutide (Wegovy) | ~15% |
| Tirzepatide (Zepbound) | ~20-22% |
| Retatrutide (Phase 3) | ~24% |
AOD-9604 is in a fundamentally different efficacy category from modern GLP-1 receptor agonists. The era of GLP-1s has rendered AOD-9604 obsolete for obesity. Users adopting AOD-9604 in 2025+ should recognize they're choosing an obsolete-class drug relative to modern alternatives.
The paradox of AOD-9604: remarkably clean safety profile (no IGF-1 elevation, no insulin resistance, no growth effects, ~900 trial participants without serious adverse events) but modest real-world efficacy. The measured effect is confined to fat loss and is modest in size; the GLP-1 agonists ([[semaglutide]], [[tirzepatide]], [[retatrutide]]) produced substantially larger weight loss in their trials.
AOD-9604's mechanism is fundamentally different from related GH-axis compounds. The compound does NOT stimulate growth hormone release (unlike [[sermorelin]] and [[cjc-1295]]); does NOT raise IGF-1 levels (notable distinguishing feature); does NOT cause insulin resistance (unlike full hGH); acts through beta-3 adrenergic receptors on adipocytes (animal data); stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis via acetyl-CoA carboxylase inhibition); is selective for adipose tissue rather than systemic GH effects. AOD-9604 should not be confused with growth hormone secretagogues, GH-axis modulators, or full hGH.
WADA-PROHIBITED: Growth hormone fragments including AOD-9604 / hGH 176-191 are listed on the WADA Prohibited List. Athletes should avoid regardless of clinical evidence.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous AOD-9604 | ~2 hours typical |
| Oral AOD-9604 | Variable; limited bioavailability |
| Sublingual AOD-9604 | Uncertain bioavailability |
| Topical AOD-9604 | Local |
What it does
Main effects
- Beta-3 adrenergic receptor activation on adipocytes: Primary mechanism (animal data); stimulates cAMP/PKA → hormone-sensitive lipase → triglyceride breakdown (lipolysis); β3 receptors predominantly on brown and white adipose tissue
- Inhibition of lipogenesis via acetyl-CoA carboxylase: Second mechanism (the original Ng group finding); rate-limiting enzyme for fatty acid synthesis blocked; net negative effect on fat storage
- NO IGF-1 elevation: Critical distinction from full hGH; avoids growth-related concerns and theoretical cancer risk of elevated IGF-1
- NO insulin resistance induction: Critical distinction from full hGH; preserves glycemic control; safer profile for diabetes-relevant applications
- NO direct growth hormone receptor activation: Despite being an hGH fragment, AOD-9604 does NOT activate GH receptors; lacks anabolic and growth-promoting effects
- Selective for adipose tissue rather than systemic GH effects: fundamentally different from full hGH; the 'lipid mobilizing domain' concept
- Modest weight loss demonstrated in the 12-week Phase 3 trial: 2.6 kg AOD-9604 vs 0.8 kg placebo (statistically significant but clinically modest)
- Australian TGA approval as cosmetic ingredient ONLY: Topical/ingestible cosmetic applications; NOT pharmaceutical approval anywhere
What to watch for
Common side effects
- FAILED Phase 3 for obesity: Insufficient weight loss magnitude for FDA approval; weight loss signal NOT seen when participants followed intensive diet/exercise programs; commercially unfeasible as obesity drug; Metabolic Pharmaceuticals (developer) is now defunct
- OBSOLETE-CLASS DRUG vs modern GLP-1 agonists: AOD-9604: 2-3 kg (3-4%) weight loss; Semaglutide: ~15%; Tirzepatide: ~20-22%; Retatrutide: ~24%. AOD-9604 is in a fundamentally different efficacy category; the era of GLP-1 receptor agonists has rendered AOD-9604 obsolete for obesity
- WADA-PROHIBITED as growth hormone fragment: Listed on WADA Prohibited List under growth hormone fragments including AOD-9604 / hGH 176-191; athletes should avoid regardless of clinical evidence
- Remarkably clean acute safety profile: Across ~900 participants in Phase 1/2/3 trials, no serious adverse events attributed to the compound; no IGF-1 elevation; no insulin resistance; no growth-related effects (carpal tunnel, edema, prostate effects); among the cleanest safety profiles in any peptide library
- Mild injection-site reactions: Occasional, generally mild
- Mild headache or fatigue: Occasional
- 'Lipid-mobilizing fragment of hGH' framing can mislead marketing: Users may expect GH-like benefits beyond fat loss; AOD-9604 does not activate growth hormone receptors, does not elevate IGF-1, and produces no anabolic or growth-promoting effects
- Combination with GH secretagogues (CJC-1295, ipamorelin) is common but defeats the selectivity advantage: Reintroduces hGH-related effects through GH secretagogues; eliminates AOD-9604's clean profile; no clinical validation of combination
- Research chemical quality concerns: Disulfide bond integrity matters; identity verification important; concentration variability; sterility for injection
- Modern context unfavorable: Pharmaceutical industry largely abandoned AOD-9604; users adopting in 2025+ should recognize this is an obsolete-class drug
- Theoretical long-term cardiovascular and bone metabolism effects: Unknown with chronic use; theoretical given growth hormone fragment origin
- Pregnancy/lactation safety unestablished
Key facts
Key facts worth knowing
- AOD-9604 is a synthetic 16-amino acid peptide corresponding to the C-terminal fragment of human growth hormone (residues 177-191) with a single Tyrosine added at the N-terminus (Tyr-hGH 177-191). Some sources describe the sequence as covering residues 176-191. Molecular weight 1817.06 Da. CAS 221231-10-3.
- Developed at Monash University (Melbourne, Australia) by Professor Frank Ng's group in the 1990s. The Ng group's foundational work identified the C-terminal fragment of hGH as containing the 'lipid mobilizing domain' with inhibitory action on acetyl-CoA carboxylase in hepatocytes and adipocytes. Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int 1993;30(1):187-196.
- Metabolic Pharmaceuticals Limited (Australian pharmaceutical company, now defunct) commercialized AOD-9604. The company pursued FDA approval pathway for obesity treatment in the early-to-mid 2000s. Failed Phase 3 outcomes ended pharmaceutical development; strategic pivot to cosmetic ingredient was insufficient for company survival.
- FAILED Phase 3 obesity trial (2007). 12-week placebo-controlled trial: AOD-9604 1 mg/day produced 2.6 kg average weight loss vs 0.8 kg placebo. Statistically significant but clinically modest. Critical follow-up: when intensive diet/exercise was incorporated, the weight loss signal disappeared. AOD-9604 effects may not add to lifestyle intervention. Combined data: insufficient magnitude for FDA approval; commercially unfeasible as obesity drug; pharmaceutical development discontinued. Phase 3 trial publication (2007) of AOD 9604 1 mg/day vs placebo. Referenced in obesity drug review (PMC 3584306).Moré JJ. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism 2014.
- AOD-9604 is essentially an obsolete-class drug relative to modern obesity treatments. Efficacy comparison: AOD-9604 ~2-3 kg (3-4%); phentermine/topiramate ~10%; liraglutide ~5-8%; semaglutide (Wegovy) ~15%; tirzepatide (Zepbound) ~20-22%; retatrutide (Phase 3) ~24%. The era of GLP-1 receptor agonists has rendered AOD-9604 obsolete for obesity. Users adopting AOD-9604 in 2025+ should recognize they're choosing an obsolete-class drug.
- Australian TGA approval as cosmetic ingredient ONLY: NOT pharmaceutical approval. After Phase 3 failure, AOD-9604 was repositioned: TGA approval under different regulatory framework as nutraceutical/cosmetic ingredient; topical and ingestible cosmetic applications; specifically NOT pharmaceutical approval anywhere. Users seeing 'TGA approved' should understand the narrow scope. Australian Therapeutic Goods Administration (TGA) approval documentation for AOD 9604 as cosmetic ingredient.
- Mechanism (animal data; less clear in humans): Beta-3 adrenergic receptor activation on adipocytes → cAMP/PKA signaling → hormone-sensitive lipase activation → triglyceride breakdown (lipolysis). Additionally, acetyl-CoA carboxylase inhibition in hepatocytes and adipocytes → reduced lipogenesis. Selective adipose tissue mechanism via β3 receptors which are predominantly on brown and white adipose tissue.
- Critical distinctions from full hGH: AOD-9604 does NOT activate growth hormone receptors; does NOT elevate IGF-1; does NOT cause insulin resistance; does NOT produce growth-related effects (carpal tunnel, edema, prostate effects, tissue growth). The selective lipolytic mechanism is the genuinely favorable feature, but the efficacy is modest. AOD-9604 should NOT be confused with: GH secretagogues (CJC-1295, ipamorelin, GHRPs; release endogenous GH, different mechanism); GH-axis modulators (sermorelin, tesamorelin; GHRH analogs, different mechanism); full hGH (somatropin, somatrem; full molecule).
- WADA-prohibited as growth hormone fragment. Growth hormone fragments including AOD-9604 / hGH 176-191 are listed on the WADA Prohibited List. Athletes should avoid regardless of clinical evidence. Specific reference to AOD-9604 appears in WADA documentation. WADA Prohibited List. Growth hormone fragments including AOD-9604 / hGH 176-191. World Anti-Doping Agency.
- Combination with GH secretagogues defeats the selectivity advantage. Many non-medical protocols combine AOD-9604 with [[cjc-1295]] and [[ipamorelin]], but this combination reintroduces hGH-related effects through the GH secretagogues, eliminates AOD-9604's clean profile, and has no clinical validation. For users specifically choosing AOD-9604 for its selective fat-loss-only profile, adding GH secretagogues defeats the entire rationale.
Legal status
Legal status
No FDA pharmaceutical approval for any indication. Failed Phase 3 obesity trials (2007); pharmaceutical development discontinued; Metabolic Pharmaceuticals is now defunct. Australian TGA approval as cosmetic ingredient ONLY: NOT pharmaceutical approval. Research chemical sale available in legal gray area. Listed on WADA Prohibited List as growth hormone fragment (verify current status for tested sport).